SCHEMBL17837006 — predicted protein targets

Predicted protein targets (top 19)

	gene	UniProt	supporting neighbours	confidence
▸	PDGFRB	P09619	11/20	1.00

▸	EGFR	P00533	10/20	1.00

▸	KDR	P35968	10/20	1.00

▸	PDGFRA	P16234	2/20	1.00

▸	TUBB4A	P04350	14/20	0.67

▸	TUBB	P07437	14/20	0.67

▸	TUBA3C	P0DPH7	14/20	0.67

▸	TUBA1B	P68363	14/20	0.67

▸	TUBA4A	P68366	14/20	0.67

▸	TUBB4B	P68371	14/20	0.67

▸	TUBB3	Q13509	14/20	0.67

▸	TUBB2A	Q13885	14/20	0.67

▸	TUBB8	Q3ZCM7	14/20	0.67

▸	TUBA3E	Q6PEY2	14/20	0.67

▸	TUBA1A	Q71U36	14/20	0.67

▸	TUBA1C	Q9BQE3	14/20	0.67

▸	TUBB6	Q9BUF5	14/20	0.67

▸	TUBB2B	Q9BVA1	14/20	0.67

▸	TUBB1	Q9H4B7	14/20	0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL17837010	0.95	EGFR (1.00)	PDGFRBEGFRKDRPDGFRATUBB4A
SCHEMBL22432673	0.88	PDGFRB (0.78)	PDGFRBEGFRKDRPDGFRATUBB4A
SCHEMBL22432671	0.83	EGFR (0.71)	PDGFRBEGFRKDRPDGFRATUBB4A
SCHEMBL16622703	0.81	TUBB4A (1.00)	PDGFRBEGFRKDRPDGFRATUBB4A
SCHEMBL18551428	0.79	TUBB4A (0.67)	PDGFRBEGFRKDRPDGFRATUBB4A
SCHEMBL16612258	0.78	TUBB4A (0.72)	PDGFRBEGFRKDRPDGFRATUBB4A
SCHEMBL16612695	0.78	TUBB4A (0.76)	PDGFRBEGFRKDRPDGFRATUBB4A
SCHEMBL16612578	0.78	TUBB4A (0.76)	PDGFRBEGFRKDRPDGFRATUBB4A
SCHEMBL19242608	0.77	EGFR (0.69)	PDGFRBEGFRKDRPDGFRATUBB4A
SCHEMBL19319608	0.77	TUBB4A (0.65)	PDGFRBEGFRKDRPDGFRATUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20200290976-A1	RADIOLABELED MICROTUBULE IMAGING COMPOUNDS AND USES THEREOF	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	2020-09-17	—	—	US	disclosed
US-10189853-B2	Conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as anti-tumor agents	DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US)	2019-01-29	—	—	US	disclosed
US-10189853-B2	Conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as anti-tumor agents	DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US)	2019-01-29	—	—	US	disclosed
US-20170369500-A1	CONFORMATIONALLY RESTRICTED 4-SUBSTITUTED-2,6-DIMETHYLFURO[2,3-d]PYRIMIDINES AS ANTI-TUMOR AGENTS	DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US)	2017-12-28	—	—	US	disclosed
US-20170369500-A1	CONFORMATIONALLY RESTRICTED 4-SUBSTITUTED-2,6-DIMETHYLFURO[2,3-d]PYRIMIDINES AS ANTI-TUMOR AGENTS	DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US)	2017-12-28	—	—	US	disclosed
US-9777012-B2	Substituted furo[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents	DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US)	2017-10-03	—	—	US	disclosed
US-9777012-B2	Substituted furo[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents	DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US)	2017-10-03	—	—	US	disclosed
US-9777012-B2	Substituted furo[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents	DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US)	2017-10-03	—	—	US	disclosed
WO-2016100495-A1	CONFORMATIONALLY RESTRICTED 4-SUBSTITUTED-2,6-DIMETHYLFURO[2,3-d]PYRIMIDINES AS ANTITUMOR AGENTS	DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US)	2016-06-23	—	—	WO	disclosed
US-20160176891-A1	Conformationally Restricted 4-Substituted-2,6-dimethylfuro[2,3-d]pyrimidines as Multi-targeted Receptor Tyrosine Kinase Inhibitors and Microtubule Targeting Antitumor Agents	DUQUESNE UNIVERSITY OF THE HOLY SPIRIT	2016-06-23	—	—	US	disclosed
US-20160176891-A1	Conformationally Restricted 4-Substituted-2,6-dimethylfuro[2,3-d]pyrimidines as Multi-targeted Receptor Tyrosine Kinase Inhibitors and Microtubule Targeting Antitumor Agents	DUQUESNE UNIVERSITY OF THE HOLY SPIRIT	2016-06-23	—	—	US	disclosed
US-20160176891-A1	Conformationally Restricted 4-Substituted-2,6-dimethylfuro[2,3-d]pyrimidines as Multi-targeted Receptor Tyrosine Kinase Inhibitors and Microtubule Targeting Antitumor Agents	DUQUESNE UNIVERSITY OF THE HOLY SPIRIT	2016-06-23	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20160176891-A1	Conformationally Restricted 4-Substituted-2,6-dimethylfuro[2,3-d]pyrimidines as Multi-targeted Receptor Tyrosine Kinase Inhibitors and Microtubule Targeting Antitumor Agents	ERBB2, MAP2, TUBB6	PDGFRB 232/4885EGFR 8/4885KDR 167/4885
US-20170369500-A1	CONFORMATIONALLY RESTRICTED 4-SUBSTITUTED-2,6-DIMETHYLFURO[2,3-d]PYRIMIDINES AS ANTI-TUMOR AGENTS	ERBB2, DCK, DHFR	PDGFRB 394/4885EGFR 38/4885KDR 402/4885
US-10189853-B2	Conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as anti-tumor agents	ERBB2, DCK, DHFR	PDGFRB 394/4885EGFR 38/4885KDR 402/4885
US-20200290976-A1	RADIOLABELED MICROTUBULE IMAGING COMPOUNDS AND USES THEREOF	TUBB3, MAP2, MAPT	PDGFRB 944/4885EGFR 1574/4885KDR 1248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.